Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Ida, Hanae; Koyama, Takafumi; Mizuno, Tadahaya; Sunami, Kuniko; Kubo, Takashi; Sudo, Kazuki; Tao, Kayoko; Hirata, Makoto; Yonemori, Kan; Kato, Ken; Okusaka, Takuji; Ohe, Yuichiro; Matsui, Yoshiyuki; Yamazaki, Naoya; Ogawa, Chitose; Kawai, Akira; Narita, Yoshitaka; Esaki, Minoru; Yamamoto, Noboru

doi:10.1111/cas.15586

Cited by 23 publications

(28 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numeric covariates were dichotomized according to standard reference values, while those without standard reference values were dichotomized in accordance with previous research or expert consensus. 3,7,37,38 For variables with missing data (BMI, neutrophils, hemoglobin, platelets, albumin, LDH, creatinine, total bilirubin, AST, and CRP), a multiple imputation was implemented under the missing at random assumption. 39 Multivariable logistic regression was estimated to assess the association of travel distance and time with genotype-matched trial participation.…”

Section: Discussionmentioning

confidence: 99%

“…CGP testing was performed using hybrid capture-based targeted DNA sequencing with FoundationOne CDx (Foundation Medicine), the OncoGuide NCC Oncopanel System (Sysmex Corporation), in-house NGS testing, or in blood-derived cell-free DNA with FoundationOne Liquid CDx (Foundation Medicine) or Guardant360 CDx (Guardant Health) . All patients were referred to the NCCH following discussion by regional molecular tumor boards (MTB) comprising medical oncologists, pediatric oncologists, pathologists, bioinformaticians, genome researchers, and genetic counselors . In addition to reports from the inspection companies, the MTBs used reports containing clinical annotation and information regarding genotype-matched clinical trials from the Center for Cancer Genomics and Advanced Therapeutics national database …”

Section: Methodsmentioning

confidence: 99%

“…Descriptive statistics were used to summarize baseline characteristics, with the χ 2 and Wilcoxon rank-sum tests applied to categorical and continuous variables, respectively. Numeric covariates were dichotomized according to standard reference values, while those without standard reference values were dichotomized in accordance with previous research or expert consensus . For variables with missing data (BMI, neutrophils, hemoglobin, platelets, albumin, LDH, creatinine, total bilirubin, AST, and CRP), a multiple imputation was implemented under the missing at random assumption …”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital

Uehara,

Koyama,

Katsuya

et al. 2023

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

ImportanceGenotype-matched trials, which are becoming increasingly important in the precision oncology era, require referrals from institutions providing comprehensive genomic profiling (CGP) testing to those conducting these trials, and the travel burden for trial participation is significant. However, it remains unknown whether travel time or distance are associated with genotype-matched trial participation.ObjectiveTo assess whether travel time or distance are associated with disparities in genotype-matched trial participation following CGP testing.Design, Setting, and ParticipantsThis retrospective cohort study from June 2020 to June 2022 included patients with advanced or metastatic solid tumors referred to the National Cancer Center Hospital for participation in genotype-matched trials following CGP testing and discussion by molecular tumor boards. Data were analyzed from June to October 2022.ExposuresTravel time and distance.Main Outcomes and MeasuresThe primary and secondary outcomes were enrollment in genotype-matched trials and all-cancer clinical trials, respectively.ResultsOf 1127 patients (mean [range] age, 62 [16-85] years; 584 women [52%]; all residents of Japan), 127 (11%) and 241 (21%) were enrolled in genotype-matched trials and all-cancer clinical trials, respectively. The overall median (IQR) travel distance and time were 38 (21-107) km and 55 (35-110) minutes, respectively. On multivariable regression with 23 covariates, travel distance (≥100 km vs &lt;100 km) was not associated with the likelihood of genotype-matched trial participation (26 of 310 patients [8%] vs 101 of 807 patients [12%]; odds ratio [OR], 0.64; 95% CI, 0.40-1.02), whereas in patients with travel time of 120 minutes or more, the likelihood of genotype-matched trial participation was significantly lower than those with travel time less than 120 minutes (19 of 276 patients [7%] vs 108 of 851 patients [13%]; OR, 0.51; 95% CI, 0.29-0.84). The likelihood of genotype-matched trial participation decreased as travel time increased from less than 40 (38 of 283 patients [13%]) to 40 to 120 (70 of 568 patients [12%]) and 120 or more (19 of 276 patients [7%]) minutes (OR, 0.74; 95% CI, 0.48-1.17; OR, 0.41; 95% CI, 0.22-0.74, respectively). Neither travel time nor distance were associated with the likelihood of all-cancer clinical trial participation.Conclusions and RelevanceIn this cohort study of patients undergoing CGP testing, an increased travel time was associated with a decreased likelihood of genotype-matched trial participation. This warrants further research on interventions, such as decentralization of clinical trials to mitigate travel burden.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital

Uehara,

Koyama,

Katsuya

et al. 2023

JAMA Netw Open

Self Cite

View full text Add to dashboard Cite

show abstract

“…The percentage of cases in which a new treatment is applied based on cancer genome pro ling, which collectively analyzes many genetic abnormalities (mutations, base substitutions, insertions/deletions, copy number abnormalities, rearrangements, fusions, etc. ), has been estimated between 10% and 20% of all patients [5][6][7]. There are higher frequencies of such cases outside of Japan; however, the present usefulness of cancer genome pro ling has not been fully con rmed here [8,9].…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Multi-Cancer Genome Profiling: Data from A Japan Hospital

Aoyama,

Nishikubo,

Kawabata

et al. 2023

Preprint

View full text Add to dashboard Cite

Aim New hopes for “precision cancer care” hinge on the success of individualized cancer genome profiling at predicting the therapeutic efficacy of various anticancer drug treatments in eligible patients. We aimed to clarify the significance of cancer genome profiling in Japan by analyzing the clinical data from cancer genome testing of various solid cancers at our hospital. Materials and Methods A total of 230 patients examined by one of three tests for multi-cancer genome profiling including NCC Oncopanel, FoundationOne CDx, and FoundationOne Liquid were retrospectively enrolled. Adequate treatment for each patient was discussed at the expert panel meeting according to the results from the genome profiling tests. Results The most frequent cancer types enrolled in this study were pancreas cancer, bowel cancer, and biliary cancer. Druggable cases comprised 108 (47%) of 230 cases, and 21 (9.1%) of 230 cases actually received medication. Partial Response (PR) was found in 7 (33%) of the 21 cases Three cases of biliary cancer and three cases of BRCA2 mutation were included among the seven PR cases. Conclusion Twenty-one (9.1%) of 230 patients were medicated in accord with multi-cancer panel data. Japanese patients with biliary tumors might derive benefit from multi-cancer genome profiling.

show abstract

“…their own data. 1 They showed that patients who received genomically matched therapy had a longer survival than those who did not.…”

mentioning

confidence: 99%

Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain

Ikegami

2023

Cancer Science

View full text Add to dashboard Cite

show abstract

Clinical utility of comprehensive genomic profiling tests for advanced or metastatic solid tumor in clinical practice

Cited by 23 publications

References 14 publications

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital

Travel Time and Distance and Participation in Precision Oncology Trials at the National Cancer Center Hospital

Clinical Significance of Multi-Cancer Genome Profiling: Data from A Japan Hospital

Prognostic benefit of comprehensive genomic profiling in clinical practice remains uncertain

Contact Info

Product

Resources

About